A 10‐month angiographic and 4‐year clinical outcome of everolimus‐eluting versus sirolimus‐eluting coronary stents in patients with diabetes mellitus (the diabedES IV randomized angiography trial). Issue 7 (6th May 2015)

• Record Type: Journal Article
• Authors: Maeng, Michael; Baranauskas, Arvydas; Christiansen, Evald Høj; Kaltoft, Anne; Holm, Niels Ramsing; Krusell, Lars Romer; Ravkilde, Jan; Tilsted, Hans‐Henrik; Thayssen, Per; Jensen, Lisette Okkels
• Is Part Of: Catheterization and cardiovascular interventions. Volume 86:Issue 7(2015:Dec. 01)
• Page Start: 1161
• Page End: 1167
• Publication Date: 2015-05-06
• Subjects: sirolimus -- everolimus -- coronary -- stent -- drug‐eluting -- randomized clinical trial; Heart -- Diseases -- Diagnosis -- Periodicals; Cardiac catheterization -- Periodicals; 616.1207572
• DOI: 10.1002/ccd.25875
• Languages: English
• ISSNs: 1522-1946

Abstract

Abstract : Objective: We aimed to compare angiographic and clinical outcomes after the implantation of everolimus‐eluting (EES) and sirolimus‐eluting (SES) stents in patients with diabetes. Background: There are limited data on long‐term outcome after EES vs SES implantation in diabetic patients. Methods: We randomized 213 patients with diabetes and coronary artery disease to EES ( n = 108) or SES ( n = 105) implantation. Angiographic follow‐up was performed 10 months after the index procedure and all patients were followed clinically for 4 years. The primary endpoint was angiographic in‐stent late luminal loss at 10‐month follow‐up. Secondary endpoints included angiographic restenosis rate, the need for target lesion revascularization (TLR) and major adverse cardiac events (MACE; defined as cardiac death, myocardial infarction, definite stent thrombosis, or TLR) at 4‐year follow‐up. Results: At 10‐month angiographic follow‐up, in‐stent late lumen loss was 0.20 ± 0.53 mm and 0.11 ± 0.49 mm ( P = 0.28), and angiographic restenosis rate was 3.8% and 5.2% ( P = 0.72) in the EES and SES groups, respectively. At 4‐year clinical follow‐up, MACE had occurred in 22 (20.4%) patients in the EES group and 25 (23.8%) patients in SES group (HR 0.84, 95% CI 0.47–1.49; P = 0.55), with TLR performed in 6 (5.6%) and 10 (9.5%) patients in the two groups (HR 0.57, 95% CI 0.21‐1‐58; P = 0.28). Conclusion: EES and SES had comparable 10‐month angiographic and 4‐year clinical outcomes in patients with diabetes mellitus and coronary artery disease. © 2015 Wiley Periodicals, Inc.